Skip to main content

Giant Cell Arteritis

4
Pipeline Programs
8
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
1
1
Secukinumab 300 mg, s.c.Phase 31 trial
Secukinumab 300 mg, s.c.Phase 21 trial
SecukinumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06130540Completed65Est. Apr 2025
NCT03765788Completed52Est. Jun 2021
NCT05380453Completed151Est. Feb 2026
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
SirukumabPhase 3Monoclonal Antibody
Chugai Pharma
Chugai PharmaJapan - Tokyo
2 programs
tocilizumab and IV steroids combinationPHASE_21 trial
TocilizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT04239196Unknown58Est. Dec 2022
NCT04888221Active Not Recruiting66Est. Aug 2025
Genentech
GenentechCA - Oceanside
1 program
TARGET GCAT RegistryN/A1 trial
Active Trials
NCT04049071Terminated80Est. Jun 2020
Kiniksa Pharmaceuticals
1 program
mavrilimumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT03827018Completed70Est. Nov 2020
Roche
RocheSTAVANGER NORWAY, Norway
1 program
tocilizumab and IV steroids combinationPHASE_2
Regeneron
RegeneronTARRYTOWN, NY
1 program
Sarilumab SAR153191PHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozSecukinumab 300 mg, s.c.
Chugai PharmaTocilizumab
Chugai Pharmatocilizumab and IV steroids combination
SandozSecukinumab 300 mg, s.c.
Kiniksa Pharmaceuticalsmavrilimumab
SandozSecukinumab
GenentechTARGET GCAT Registry

Clinical Trials (7)

Total enrollment: 542 patients across 7 trials

NCT05380453SandozSecukinumab 300 mg, s.c.

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

Start: Sep 2022Est. completion: Feb 2026151 patients
Phase 3Completed
NCT04888221Chugai PharmaTocilizumab

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement

Start: Sep 2021Est. completion: Aug 202566 patients
Phase 3Active Not Recruiting
NCT04239196Chugai Pharmatocilizumab and IV steroids combination

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

Start: Sep 2020Est. completion: Dec 202258 patients
Phase 2Unknown
NCT03765788SandozSecukinumab 300 mg, s.c.

A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis

Start: Jan 2019Est. completion: Jun 202152 patients
Phase 2Completed
NCT03827018Kiniksa Pharmaceuticalsmavrilimumab

KPL-301 for Subjects With Giant Cell Arteritis

Start: Sep 2018Est. completion: Nov 202070 patients
Phase 2Completed
NCT06130540SandozSecukinumab

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Start: Mar 2024Est. completion: Apr 202565 patients
Phase 1Completed
NCT04049071GenentechTARGET GCAT Registry

TARGET GCAT Registry

Start: May 2019Est. completion: Jun 202080 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.